Exforge^Ŵ (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact

References

• Lawes C, Vander Hoorn S, Rodgers A; for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–19.
   PubMed Web of Science ®Google Scholar
• Pardell H, Tresserras R, Armario P, Hernánez del Rey. Pharmacoeconomic considerations in the management of hypertension. Drugs. 2000;59(Suppl 2):12–20.
   Google Scholar
• Goetzel R, Long S, Ozminkowski R, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004,46:398–412.
   PubMed Web of Science ®Google Scholar
• Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003–2004. Hypertension. 2008;51: 1275–1281.
   PubMed Web of Science ®Google Scholar
• Erdine S. How well is hypertension controlled in Europe? ESH Newsletter. 2007;8:No. 3. Available at: http://www.eshonline.org/education/newsletter.php.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension, task force of the European Society of Hypertension and the European Society of Cardiology. J Hypertension. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16:569–575.
   PubMed Web of Science ®Google Scholar
• Yusuf F, Sleight P, Dagenais G, et al. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-convertingenzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153.
   PubMed Web of Science ®Google Scholar
• Yusuf F, Sleight P, Anderson C, et al. the ONTARGET investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Alderman M, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594–598.
   PubMed Web of Science ®Google Scholar
• Stafford RS, Monti V, Furberg CD, Ma J. Long term and short term changes in antihypertensive prescribing by office based physicians in the United States. Hypertension. 2006;48:213–218.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762.
   PubMed Web of Science ®Google Scholar
• K/DOQI (Kidney Disease Outcomes Quality Initiative) Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Measurement of blood pressure in adults. Am J Kidney Dis. 2004;43:S92–S106.
   Google Scholar
• Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med. 2005;353:487–497.
   PubMed Web of Science ®Google Scholar
• Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001;19:149–155.
   PubMed Web of Science ®Google Scholar
• Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005;19:491–496.
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Makris B, Papavasiliou M, Efstahiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23:883–889.
   PubMed Web of Science ®Google Scholar
• Berlowitz D, Ash A, Hickey E, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339: 1957–1963.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005;28:385–407.
   PubMed Web of Science ®Google Scholar
• LeLorier J. The value of lowering blood pressure. Can J Cardiol. 2006;22:63–64.
   PubMed Web of Science ®Google Scholar
• van Zwieten P. Beneficial combinations of two or more antihypertensive agents. ESH-Newsletter. 2003;4:No.18. Available at: http://www.eshonline.org/education/newsletter.php.
   Google Scholar
• de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens. 2007;9:168–178.
   PubMedGoogle Scholar
• Burges RA, Gardiner DG, Gwilt M, et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. J Cardiovasc Pharmacol. 1987;9:110–119.
   PubMed Web of Science ®Google Scholar
• Padia S, Howell N, Siragy H, Carey R. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537–544.
   PubMed Web of Science ®Google Scholar
• Franco M, Sanchez-Lozada LG, Bautista R, Johnson RJ, Rodriguez- Iturbe B. Pathophysiology of salt-sensitive hypertension: a new scope of an old problem. Blood Purif. 2008;26:45–48.
   PubMed Web of Science ®Google Scholar
• EMEA (European Medicines Agency). 2007. Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/exforge.
   Google Scholar
• Plosker G, Robinson D. Amlodipine/valsartan fixed-dose combination in hypertension. Drugs. 2008;68:373–381.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211–2221.
   PubMed Web of Science ®Google Scholar
• Karas M, Lacourcière Y, LeBlanc AR, et al. Effects of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens. 2005;23:1251–1260.
   PubMed Web of Science ®Google Scholar
• Nissen S, Tuzcu M, Libby R, et al. for CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure; the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–2226.
   PubMed Web of Science ®Google Scholar
• CAFE Investigators. Differential impact of blood pressure lowering drugs on the central aortic pressure and clinical outcomes. Circulation. 2006;113:1213–1225.
   PubMed Web of Science ®Google Scholar
• Nathan S, Pepine CL, Bakris GL. Calcium antagonists – effects on cardiorenal risk in hypertensive patients. Hypertension. 2005;46:637–642.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Roto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008;73:1303–1309.
   PubMed Web of Science ®Google Scholar
• Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens. 2004;17:638–639; author reply 639–640.
   PubMedGoogle Scholar
• Agodoa L, Appel L, Bakris G and The African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001;285:2719–2728.
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Glynn RJ; for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein. Primary report of the Val-MARC trial. Hypertension. 2006;48:73–79.
   PubMed Web of Science ®Google Scholar
• Galle J, Schwedhelm E, Pinnetti S, Böger H, Wanner C; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008;23:3174–3183.
   PubMed Web of Science ®Google Scholar
• Wogen J, Kreillick Ca, Livornesse RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usualcare setting. J Manag Care Pharm. 2003;9:424–429.
   PubMedGoogle Scholar
• Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20:72–80.
   PubMed Web of Science ®Google Scholar
• Mason RP, Marche R Hintze TH. Novel vascular biology of thirdgeneration L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155–2163.
   PubMed Web of Science ®Google Scholar
• Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70: 2109–2115.
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Kimura Y, Sagaro Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30:267–276.
   PubMed Web of Science ®Google Scholar
• Maeda T, Kata M, Tajima A, et al. Additive effect of valsartan on exercise tolerance in hypertensive patients treated with amlodipine. J Hypertens. 2006;24(Suppl 6):399. Abstract PO4–154.
   Google Scholar
• Allemann Y, Fraile B, Lambert M, Barbier M, Ferber R, Izzo J. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy (EX-FAST) study. J Clin Hyperten (Greenwich). 2008;10:185–194.
   PubMed Web of Science ®Google Scholar
• Poldermans D, Glazer R, Karagiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adults patients with stage 2 hypertension. Clin Ther. 2007;29:279–289.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Mugelini A, et al. Comparative evaluation of effect of valsartan/amlodipine and valsartan and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2008;51: 217–222.
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A, et al. Effects of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007a;20:417–422.
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith T, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563–580.
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9:335–364.
   Google Scholar
• Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. Journal of the American Society of Hypertension. 2008;2:294–302.
   PubMed Web of Science ®Google Scholar
• Trenkwalder R, Schaetz R, Borbas E, et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 – The EXPRESS-C trial. J Hypertens. 2007:P24.261. Abstract S225.
   Google Scholar
• Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther. 2008;25: 399–411.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007b;20:220–224.
   Google Scholar
• Jönsson B, Hansson L, Stålhammar N-O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and costeffectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med. 2003;253:472–480.
   PubMed Web of Science ®Google Scholar
• Dalhöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Valsartan in Acute Myocardial Infarction (VALIANT) Trial Investigators. N Engl J Med. 2003;349: 1893–1906.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure; Valsartan Heart Failure Trial (Val-HeFT) Investigators. N Engl J Med. 2001;345:1667–1675. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmaco Economics. 2001;19: 337–347.
   PubMed Web of Science ®Google Scholar